Compass Therapeutics: CEO change to Bisker-Leib, CTX-471 CR in SCLC, $152M cash

Compass Therapeutics, Inc.

CEO succession: Vered Bisker-Leib appointed CEO effective Jan 9, 2024; Thomas Schuetz becomes President of R&D and Vice Chair.
Year-end 2023 cash & securities ~$152M, providing runway into mid-2026.
CTX-471: SCLC patient partial response converted to complete response; new PR in melanoma yields 27% ORR (3/11).
CTX-009: COMPANION-003 top-line data expected mid-2024; COMPANION-002 top-line data in H2 2024.
CTX-8371 IND accepted; first patient dosing expected in Q1 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.